Fas ligand expression in nodal non-Hodgkin's lymphoma

Autor:	Leonhard Müllauer, Mosberger I, Chott A
Rok vydání:	1998
Předmět:	B-Lymphocytes Jurkat Cells Fas Ligand Protein Lymphoma B-Cell Membrane Glycoproteins Lymphoma Non-Hodgkin Tumor Cells Cultured Humans Lymphoma Large-Cell Anaplastic Lymphoma T-Cell Peripheral Lymph Nodes Lymphoma T-Cell Immunohistochemistry
Zdroj:	Web of Science Scopus-Elsevier Europe PubMed Central
ISSN:	0893-3952
Popis:	Fas (Apo-1/CD95) ligand (FasL) is a cytotoxic molecule used by T lymphocytes and natural killer cells for target-cell killing and by nonmalignant and malignant cells in the suppression of immune responses. In this study, FasL expression in B- and T-cell non-Hodgkin's lymphomas was investigated by paraffin immunohistochemical analysis. FasL expression was found to be weak in nonaggressive lymphomas (chronic lymphocytic leukemia/small lymphocytic lymphoma, lymphoplasmacytoid lymphoma, Grade 1 follicular center cell lymphoma) and mantle cell lymphoma but strong in aggressive B-cell lymphomas (diffuse large B-cell lymphoma, Burkitt's-lymphoma). Precursor B-lymphoblastic lymphomas were more heterogeneous, with expression varying from weak to strong. In T-cell lymphomas (anaplastic large-cell lymphoma; peripheral T-cell lymphoma, unspecified), strong FasL expression was observed. Apparently, FasL expression is not limited to neoplasms derived from T cells or natural killer cells, and it might play a supporting role in the progression of non-Hodgkin's lymphomas.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::5caa604ab0277fd9c08607c679f937cf https://pubmed.ncbi.nlm.nih.gov/9578088 Zobrazit plný text záznamu